Literature DB >> 6658720

Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously.

D Bergqvist, U Hedner, E Sjörin, E Holmer.   

Abstract

Two types of LMW heparin were prepared by gel filtration of standard heparin (LMW fraction) and by degradation of heparin by nitrous acid (LMW fragment), respectively. The effects on factor Xa inhibition (XaI), APTT, platelet aggregation and AT III level of these preparations were studied after subcutaneous administration to humans and compared with those of standard heparin. At a dose of 5000 IU (XaI) the LMW fraction and LMW fragment induced peak plasma XaI activity of 0.32 IU/ml and 0.41 IU/ml respectively, compared to 0.07 IU/ml for heparin. Still 11.5 h after administration both LMW preparations gave higher activities than heparin ever induced. Following administration of 10,000 IU (XaI) of the LMW fragment the plasma peak XaI activity was 0.81 IU/ml. This prolonged the APTT from 36 sec to 46 sec only. The half-lives of the XaI activity in plasma were between 3 and 4 hours. No effect on platelet aggregation or AT-III level was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6658720     DOI: 10.1016/0049-3848(83)90091-9

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  9 in total

1.  [Different effectiveness of two preparations of low molecular weight heparin in patients with elective hip joint replacement].

Authors:  U Weber; K Koppenhagen; H Mälzer; M Matthes
Journal:  Langenbecks Arch Chir       Date:  1991

2.  [Neutralization of low molecular weight heparin Kabi 2165 by protamine chloride].

Authors:  J Harenberg; C Giese; A Knödler; R Zimmermann; G Schettler
Journal:  Klin Wochenschr       Date:  1986-11-17

3.  Inhibition of coagulation and platelet adhesion to extracellular matrix by unfractionated heparin and a low molecular weight heparin.

Authors:  K Krupinski; M Basic-Micic; E Lindhoff; H K Breddin
Journal:  Blut       Date:  1990-11

4.  Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

Authors:  G F Handeland; U Abildgaard; H A Holm; K E Arnesen
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  Prophylaxis of venous thromboembolism.

Authors:  V V Kakkar; M D Stringer
Journal:  World J Surg       Date:  1990 Sep-Oct       Impact factor: 3.352

6.  Treatment of Venous Thromboembolism with Low-Molecular-Weight Heparin.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

7.  A prospective randomized trial of low molecular weight heparin-DHE and conventional heparin-DHE (with acenocoumarol) in patients undergoing gynaecological surgery.

Authors:  R A Steiner; K Keller; T Lüscher; W E Schreiner
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

Review 8.  Low molecular weight heparins. An objective overview.

Authors:  D Hoppensteadt; J M Walenga; J Fareed
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

Review 9.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.